Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/22817
Title: Antibody-based assay discriminates Zika virus infection from other flaviviruses
Authors: Balmaseda, Angel
Stettler, Karin
Medialdea-Carrera, Raquel
Collado, Damaris
Jin, Xia
Zambrana, José Victor
Jaconi, Stefano
Cameroni, Elisabetta
Saborio, Saira
Rovida, Francesca
Percivalle, Elena
Ijaz, Samreen
Dicks, Steve
Ushiro-Lumb, Ines
Barzon, Luisa
Siqueira, Patricia
Brown, David W. G.
Baldanti, Fausto
Tedder, Richard
Zambon, Maria
Filippis, A. M. Bispo de
Harris, Eva
Corti, Davide
Affilliation: Ministry of Health. Centro Nacional de Diagnóstico y Referencia. Laboratorio Nacional de Virología. Managua, Nicaragua / .Sustainable Sciences Institute. Managua 14007, Nicaragua.
Humabs BioMed SA, 6500 Bellinzona, Switzerland.
University of Liverpool. National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections. Liverpool, United Kingdom.
Sustainable Sciences Institute. Managua 14007, Nicaragua.
Humabs BioMed SA, 6500 Bellinzona, Switzerland.
Sustainable Sciences Institute. Managua 14007, Nicaragua.
Humabs BioMed SA, 6500 Bellinzona, Switzerland.
Humabs BioMed SA, 6500 Bellinzona, Switzerland.
Ministry of Health. Centro Nacional de Diagnóstico y Referencia. Laboratorio Nacional de Virología. Managua, Nicaragua / .Sustainable Sciences Institute. Managua 14007, Nicaragua.
Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo. Molecular Virology Unit, Microbiology and Virology Department. Pavia, Italy.
Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo. Molecular Virology Unit, Microbiology and Virology Department. Pavia, Italy.
Public Health England. Microbiology Services Colindale. Londo, United Kingdom.
Public Health England. Microbiology Services Colindale. Londo, United Kingdom.
Microbiology Services. National Health Service Blood and Transplant. London, United Kingdom.
University of Padova. Department of Molecular Medicine. Padova, Italy.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil.
Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo. Molecular Virology Unit, Microbiology and Virology Department. Pavia, Italy / University of Pavia. Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences. Pavia, Italy.
Public Health England. Microbiology Services Colindale. Londo, United Kingdom.
Public Health England. Microbiology Services Colindale. Londo, United Kingdom.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil.
University of California. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
Humabs BioMed SA, 6500 Bellinzona, Switzerland.
Abstract: Zika virus (ZIKV) is a mosquito-borne flavivirus that emerged recently as a global health threat, causing a pandemic in the Americas. ZIKV infection mostly causes mild disease, but is linked to devastating congenital birth defects and Guillain-Barré syndrome in adults. The high level of cross-reactivity among flaviviruses and their cocirculation has complicated serological approaches to differentially detect ZIKV and dengue virus (DENV) infections, accentuating the urgent need for a specific and sensitive serological test. We previously generated a ZIKV nonstructural protein 1 (NS1)-specific human monoclonal antibody, which we used to develop an NS1-based competition ELISA. Well-characterized samples from RT-PCR-confirmed patients with Zika and individuals exposed to other flavivirus infections or vaccination were used in a comprehensive analysis to determine the sensitivity and specificity of the NS1 blockade-of-binding (BOB) assay, which was established in laboratories in five countries (Nicaragua, Brazil, Italy, United Kingdom, and Switzerland). Of 158 sera/plasma from RT-PCR-confirmed ZIKV infections, 145 (91.8%) yielded greater than 50% inhibition. Of 171 patients with primary or secondary DENV infections, 152 (88.9%) scored negative. When the control group was extended to patients infected by other flaviviruses, other viruses, or healthy donors (n = 540), the specificity was 95.9%. We also analyzed longitudinal samples from DENV-immune and DENV-naive ZIKV infections and found inhibition was achieved within 10 d postonset of illness and maintained over time. Thus, the Zika NS1 BOB assay is sensitive, specific, robust, simple, low-cost, and accessible, and can detect recent and past ZIKV infections for surveillance, seroprevalence studies, and intervention trials.
Keywords: Zika
serology
flaviruses
dengue
ELISA
keywords: Zika
Dengue
ELISA
Sorologia
Flavivirus
Issue Date: 2017
Publisher: National Academy of Sciences
Citation: BALMASEDA, Angel; et al. Antibody-based assay discriminates Zika virus infection from other flaviviruses. PNAS Early Edition, 6p, 2017.
DOI: 10.1073/pnas.1704984114
ISSN: 1091-6490
Copyright: open access
Appears in Collections:IOC - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
david_brown_etal_IOC_2017.pdfArtigo principal853.92 kBAdobe PDFView/Open
supporting information.pdfSupporting Information Balmaseda et al500.75 kBAdobe PDFView/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.